25710-18-3

Basic information

• Product Name: 2,3-DICHLORO-PYRIDO[2,3-B]PYRAZINE
• Synonyms: 2,3-DICHLORO-PYRIDO[2,3-B]PYRAZINE
• CAS NO: 25710-18-3
• Molecular Formula: C₇H₃Cl₂N₃
• Molecular Weight: 200.02482
• Mol File: 25710-18-3.mol
• Article Data: 11

Chemical Properties

• Melting Point: 144-146 °C
• Boiling Point: 282.342°C at 760 mmHg
• Flash Point: 151.584°C
• Appearance: /
• Density: 1.573g/cm³
• Vapor Pressure: 0.006mmHg at 25°C
• Refractive Index: 1.682
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.19±0.30(Predicted)
• CAS DataBase Reference: 2,3-DICHLORO-PYRIDO[2,3-B]PYRAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-DICHLORO-PYRIDO[2,3-B]PYRAZINE(25710-18-3)
• EPA Substance Registry System: 2,3-DICHLORO-PYRIDO[2,3-B]PYRAZINE(25710-18-3)

Safety Data

• Hazardous Substances Data: 25710-18-3(Hazardous Substances Data)

Usage

General Description

2,3-Dichloro-pyrido[2,3-b]pyrazine is a chemical compound with the molecular formula C6H3Cl2N3. It is a heterocyclic organic compound that contains both a pyridine and pyrazine ring, with chlorine atoms attached to the 2 and 3 positions of the pyridine ring. 2,3-DICHLORO-PYRIDO[2,3-B]PYRAZINE is commonly used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. It is also used as a building block in organic synthesis to create more complex compounds. 2,3-Dichloro-pyrido[2,3-b]pyrazine is highly reactive and can be potentially hazardous if mishandled, requiring careful storage and handling in a controlled laboratory environment.

InChI:InChI=1/C7H3Cl2N3/c8-5-6(9)12-7-4(11-5)2-1-3-10-7/h1-3H

Upstream product

• 2067-84-7 pyrido[3,2-b]pyrazine-2,3-diol 
• 452-58-4 2,3-Diaminopyridine 
• 144-62-7 oxalic acid 
• 2067-84-7 NSC 91561 

Downstream Products

• 1338227-54-5 2-chloro-3-(phenylethynyl)pyrido[3,2-b]pyrazine 

Relevant articles and documents

Discovery of a Novel Highly Selective Histamine H4 Receptor Antagonist for the Treatment of Atopic Dermatitis

The histamine H4 receptor (H4R), a member of the G-protein coupled receptor family, has been considered as a potential therapeutic target for treating atopic dermatitis (AD). A large number of H4R antagonists have been disclosed, but no efficient agents controlling both pruritus and inflammation in AD have been developed yet. Here, we have discovered a novel class of orally available H4R antagonists showing strong anti-itching and anti-inflammation activity as well as excellent selectivity against off-targets. A pharmacophore-based virtual screening system constructed in-house successfully identified initial hit compound 9, and the subsequent homology model-guided optimization efficiently led us to discover pyrido[2,3-e]tetrazolo[1,5-a]pyrazine analogue 48 as a novel chemotype of a potent and highly selective H4R antagonist. Importantly, orally administered compound 48 exhibits remarkable efficacy on antipruritus and anti-inflammation with a favorable pharmacokinetic (PK) profile in several mouse models of AD. Thus, these data strongly suggest that our compound 48 is a promising clinical candidate for treatment of AD.

Synthesis and evaluation of F-18 labeled pyrido[3,2-B]pyrazine derivative as a potential imaging agent for non-small-cell lung cancer

Pyridopyrazine derivatives have been known as Wnt-2/β-catenin signaling pathway inhibitors. Wnt-2 overexpression may be involved in non-small-cell lung cancer (NSCLC). A novel 2-(4-[18 F]fluorobutoxy)-3-(phenylethynyl)pyrido[3,2-b]pyrazine was prepared to demonstrate the feasibility of NSCLC imaging agent by uptake of Wnt-2 protein. It was synthesized with tosylated precursor using [18F]fluoride in radiochemical yield of 44-48%. In cellular uptake evaluation, H460 and H1299, Wnt-2 expressed cancer cell lines, showed 2.5-folds higher cellular uptake than that of MCF10A as a control.

IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS

The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed.